Betaxolol and levobunolol: new beta-blocking antiglaucoma agents.
The Food and Drug Administration has recently approved the use of two new ophthalmic beta-adrenergic antagonistic agents: betaxolol hydrochloride (Betoptic) and levobunolol hydrochloride (Betagan). This paper reviews the history, pharmacologic properties, clinical efficacy and potential side effects of this expanding class of antiglaucoma medication.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D015784:Betaxolol; D055598:Chemical Phenomena; D002621:Chemistry; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D002040:Levobunolol / Q000009:adverse effects / Q000627:therapeutic use*; D011412:Propanolamines / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D002040:Levobunolol; D015784:Betaxolol